Beyond the breakthrough

Radiopharmaceuticals. Science is only half the story.

Radiopharmaceutical innovation accelerates with success depending on more than eureka moments. Explore expert perspectives on the operational, regulatory and commercial realities framing the future.

Research & Development

Advancing Radiopharmaceuticals From Regulatory Approval to Global Access

Research & Development | White Paper Advancing Radiopharmaceuticals From Regulatory Approval to Global Access

Wall Street Perspective on Radiopharmaceuticals Image

Commercialization & Access | White Paper Wall Street Perspective on Radiopharmaceuticals

Navigating Global Regulations for Radiopharmaceutical Development Image

Research & Development | White Paper Navigating Global Regulations for Radiopharmaceutical Development

Challenges and Opportunities for Radiopharmaceutical Commercialization Image

Commercialization & Access | White Paper Challenges and Opportunities for Radiopharmaceutical Commercialization

Managing Operational Complexity in Early-Phase Oncology Radiopharmaceutical Trials Image

Research & Development | White Paper Managing Operational Complexity in Early-Phase Oncology Radiopharmaceutical Trials

Radiopharm excellence

Expertise has no half-life

Precision teams make sense of the science and logistics of radiopharmaceutical therapies, from development to access and adoption.

Precision AQ Greg Gregory, PhD

Find out more

Precision AQ Stephanie Kennedy, PhD

Find out more

Precision AQ Julianna Kula, PharmD, BCOP

Find out more

Angelica Norrell, PharmD, BCOP, CSP Image

Precision AQ Angelica Norrell, PharmD, BCOP, CSP

Find out more

Precision AQ Cherry Moldovan, PhD

Find out more

Precision AQ Hannah Deresiewicz

Find out more

Precision AQ Anne Marie Fields

Find out more

Precision AQ Andrew Dymon

Find out more

Precision for Medicine Nicholas Richardson, DO, MPH

Find out more

Precision for Medicine John McIntyre, PhD

Find out more

Precision for Medicine Harpreet Singh, MD

Find out more

Precision for Medicine Jing Ping Yeo, PhD, MBA

Find out more

Precision for Medicine Geoffrey Kannan, PhD, MD

Find out more

Precision for Medicine Ivan Barrera, MD

Find out more

Precision for Medicine Robert Bauer

Find out more

Precision for Medicine Kurt Preugschat

Find out more

Navigating the landscape

The path from promise to practice

Decisions made in one area can create opportunities, or constraints, across the entire product lifecycle.

Development Designing for reality early

Radiopharmaceutical development demands early consideration of access, infrastructure and evidence. Decisions made during trial planning can influence success long after approval.

Operations Keeping progress moving forward

Short half-lives, site readiness and supply co-ordination leave little room for error. Understanding operational pressure points can help prevent a delay becoming a roadblock.

Commercialization Accelerating into adoption

Approval is just the gateway. Reimbursement, provider readiness and community activation all influence whether radiopharmaceutical innovation reaches its full potential.

What’s next

Stay tuned

Keep up with the insights helping teams stay one step ahead, from emerging regulations and operational realities to commercialization strategies and market trends.

Questions answered

Radiopharma FAQs

Explore answers to some of the most common questions surrounding radiopharma, from innovation to clinical trials, regulation and patient access.

What are radiopharmaceuticals?

These are medicines containing radioactive isotopes that can be used to diagnose and treat disease. In oncology, they offer a targeted approach by delivering radiation directly to tumor cells while limiting exposure to healthy tissues.

Why are radiopharmaceuticals gaining momentum?

In oncology, they offer a targeted approach by delivering radiation directly to tumor cells while limiting exposure to healthy tissue.

How is radiopharmaceutical development different from other therapies?

Radiopharmaceuticals introduce unique scientific and operational considerations. Short isotope half-lives, specialized manufacturing requirements and complex logistics can create challenges rarely encountered in traditional drug development.

What can delay radiopharmaceutical trials?

Site readiness, isotope availability, logistics, patient scheduling and regulatory requirements can all create bottlenecks. Identifying operational risks early can help reduce disruption.

Why are global regulations so complex?

Regulatory frameworks vary across regions and often reflect differences in healthcare systems, nuclear medicine infrastructure and local requirements. Understanding these differences early can help avoid delays.

Does approval guarantee patient access?

No. Regulatory approval is a significant milestone, but it is only one step in the journey. Reimbursement pathways, treatment infrastructure and healthcare system readiness all influence patient access.

What are the biggest commercialization challenges?

Commercialization requires aligning providers, treatment centers, payers and healthcare systems. Capacity constraints, reimbursement considerations and operational complexity can all affect uptake.

What will shape radiopharma's future?

Innovation in targeting technologies, isotope development and combination therapies will help shape the future of the field, alongside advances in manufacturing, supply infrastructure and patient access.